{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:15:40Z","timestamp":1791976540723,"version":"4.4.0"},"reference-count":73,"publisher":"The Endocrine Society","issue":"7","license":[{"start":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T00:00:00Z","timestamp":1648944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,16]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Context<\/jats:title><jats:p>Data on long-term safety of growth hormone (GH) replacement in adults with GH deficiency (GHD) are needed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>We aimed to evaluate the safety of GH in the full KIMS (Pfizer International Metabolic Database) cohort.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The worldwide, observational KIMS study included adults and adolescents with confirmed GHD. Patients were treated with GH (Genotropin [somatropin]; Pfizer, NY) and followed through routine clinical practice. Adverse events (AEs) and clinical characteristics (eg, lipid profile, glucose) were collected.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A cohort of 15 809 GH-treated patients were analyzed (mean follow-up of 5.3 years). AEs were reported in 51.2% of patients (treatment-related in 18.8%). Crude AE rate was higher in patients who were older, had GHD due to pituitary\/hypothalamic tumors, or adult-onset GHD. AE rate analysis adjusted for age, gender, etiology, and follow-up time showed no correlation with GH dose. A total of 606 deaths (3.8%) were reported (146 by neoplasms, 71 by cardiac\/vascular disorders, 48 by cerebrovascular disorders). Overall, de novo cancer incidence was comparable to that in the general population (standard incidence ratio 0.92; 95% CI, 0.83-1.01). De novo cancer risk was significantly lower in patients with idiopathic\/congenital GHD (0.64; 0.43-0.91), but similar in those with pituitary\/hypothalamic tumors or other etiologies versus the general population. Neither adult-onset nor childhood-onset GHD was associated with increased de novo cancer risks. Neutral effects were observed in lipids\/fasting blood glucose levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These final KIMS cohort data support the safety of long-term GH replacement in adults with GHD as prescribed in routine clinical practice.<\/jats:p><\/jats:sec>","DOI":"10.1210\/clinem\/dgac199","type":"journal-article","created":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T06:31:33Z","timestamp":1648967493000},"page":"1906-1919","source":"Crossref","is-referenced-by-count":41,"title":["Long-term Safety of Growth Hormone in Adults With Growth Hormone Deficiency: Overview of 15 809 GH-Treated Patients"],"prefix":"10.1210","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3484-8440","authenticated-orcid":false,"given":"Gudmundur","family":"Johannsson","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Sahlgrenska University Hospital & Institute of Medicine, Sahlgrenska Academy, University of Gothenburg , SE-413 45, Gothenburg , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8462-7753","authenticated-orcid":false,"given":"Philippe","family":"Touraine","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Reproductive Medicine, Center for Rare Endocrine and Gynecological Disorders, Sorbonne Universit\u00e9 , Assistance Publique Hopitaux de Paris, Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5903-3355","authenticated-orcid":false,"given":"Ulla","family":"Feldt-Rasmussen","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Rigshospitalet, and Department of Clinical Medicine, Faculty of Health and Clinical Science, Copenhagen University , Copenhagen , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7549-7563","authenticated-orcid":false,"given":"Antonio","family":"Pico","sequence":"additional","affiliation":[{"name":"Biomedical Research Networking Center in Rare Diseases (CIBERER), Institute of Health Carlos III (ISCIII) , Madrid , Spain"},{"name":"Hospital General Universitario de Alicante-Institute for Health and Biomedical Research (ISABIAL) , Alicante , Spain"},{"name":"Department of Clinical Medicine, Miguel Hern\u00e1ndez University , Elche , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1918-1959","authenticated-orcid":false,"given":"Greisa","family":"Vila","sequence":"additional","affiliation":[{"name":"Clinical Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders F","family":"Mattsson","sequence":"additional","affiliation":[{"name":"Pfizer Endocrine Care, Pfizer Health AB , Sollentuna , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3106-0754","authenticated-orcid":false,"given":"Martin","family":"Carlsson","sequence":"additional","affiliation":[{"name":"Rare Disease, Biopharmaceuticals, Pfizer , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4101-9432","authenticated-orcid":false,"given":"M\u00e1rta","family":"Korbonits","sequence":"additional","affiliation":[{"name":"Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 P","family":"van Beek","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, University Medical Center Groningen, University of Groningen , Groningen , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P","family":"Wajnrajch","sequence":"additional","affiliation":[{"name":"Rare Disease, Biopharmaceuticals, Pfizer , New York, NY , USA"},{"name":"Department of Pediatrics, New York University Langone Medical Center , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7029-1542","authenticated-orcid":false,"given":"Roy","family":"Gomez","sequence":"additional","affiliation":[{"name":"European Medical Affairs , Pfizer, Brussels , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8169-2728","authenticated-orcid":false,"given":"Kevin C J","family":"Yuen","sequence":"additional","affiliation":[{"name":"Barrow Pituitary Center, Barrow Neurological Institute, University of Arizona College of Medicine and Creighton School of Medicine , Phoenix, AZ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,4,3]]},"reference":[{"issue":"Suppl 1","key":"2022061616021303000_CIT0001","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1530\/EJE-09-0273","article-title":"Etiology, baseline characteristics, and biochemical diagnosis of GH deficiency in the adult: are there regional variations?","volume":"161","author":"Brabant","year":"2009","journal-title":"Eur J Endocrinol."},{"issue":"2","key":"2022061616021303000_CIT0002","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1210\/jc.2008-0713","article-title":"Changing patterns of the adult growth hormone deficiency diagnosis documented in a decade-long global surveillance database","volume":"94","author":"Webb","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"26","key":"2022061616021303000_CIT0003","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1056\/NEJMra1817346","article-title":"Pathogenesis and diagnosis of growth hormone deficiency in adults","volume":"380","author":"Melmed","year":"2019","journal-title":"N Engl J Med."},{"key":"2022061616021303000_CIT0004","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3389\/fendo.2013.00064","article-title":"Adult growth hormone deficiency - benefits, side effects, and risks of growth hormone replacement","volume":"4","author":"Reed","year":"2013","journal-title":"Front Endocrinol."},{"issue":"6","key":"2022061616021303000_CIT0005","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/joim.13382","article-title":"Growth hormone deficiency in adults with hypopituitarism-what are the risks and can they be eliminated by therapy?","volume":"290","author":"Johannsson","year":"2021","journal-title":"J Intern Med."},{"issue":"1","key":"2022061616021303000_CIT0006","doi-asserted-by":"crossref","first-page":"R47","DOI":"10.1530\/EJE-18-0306","article-title":"Therapy of endocrine disease: growth hormone replacement therapy in adults: 30 years of personal clinical experience","volume":"179","author":"Jorgensen","year":"2018","journal-title":"Eur J Endocrinol."},{"issue":"1","key":"2022061616021303000_CIT0007","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1530\/EJE-07-0013","article-title":"Mortality and GH deficiency: a nationwide study","volume":"157","author":"Stochholm","year":"2007","journal-title":"Eur J Endocrinol."},{"issue":"4","key":"2022061616021303000_CIT0008","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1210\/jc.2014-3787","article-title":"Excess mortality associated with hypopituitarism in adults: a meta-analysis of observational studies","volume":"100","author":"Pappachan","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2022061616021303000_CIT0009","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1530\/EJE-11-0558","article-title":"Body composition and quality of life in adults treated with GH therapy: a systematic review and meta-analysis","volume":"166","author":"Hazem","year":"2012","journal-title":"Eur J Endocrinol."},{"issue":"5","key":"2022061616021303000_CIT0010","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1210\/jc.2003-030840","article-title":"Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a metaanalysis of blinded, randomized, placebo-controlled trials","volume":"89","author":"Maison","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2022061616021303000_CIT0011","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1210\/jc.2013-3921","article-title":"Effects of recombinant human growth hormone therapy on bone mineral density in adults with growth hormone deficiency: a meta-analysis","volume":"99","author":"Barake","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2022061616021303000_CIT0012","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1210\/jc.2003-030134","article-title":"Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H)","volume":"89","author":"Rosilio","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2022061616021303000_CIT0013","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1210\/jc.2006-1487","article-title":"A 10-year, prospective study of the metabolic effects of growth hormone replacement in adults","volume":"92","author":"Gotherstrom","year":"2007","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2022061616021303000_CIT0014","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1210\/jc.2012-2940","article-title":"Metabolic profile in growth hormone-deficient (GHD) adults after long-term recombinant human growth hormone (rhGH) therapy","volume":"98","author":"Claessen","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"2022061616021303000_CIT0015","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1210\/jc.2011-1215","article-title":"Does growth hormone replacement therapy reduce mortality in adults with growth hormone deficiency? Data from the Dutch National Registry of Growth Hormone Treatment in adults","volume":"96","author":"van Bunderen","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2022061616021303000_CIT0016","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/EJE-12-1088","article-title":"Long-term effects of recombinant human GH replacement in adults with GH deficiency: a systematic review","volume":"169","author":"Appelman-Dijkstra","year":"2013","journal-title":"Eur J Endocrinol."},{"issue":"Suppl 1","key":"2022061616021303000_CIT0017","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1530\/EJE-09-0287","article-title":"Safety aspects of GH replacement","volume":"161","author":"Svensson","year":"2009","journal-title":"Eur J Endocrinol."},{"issue":"4","key":"2022061616021303000_CIT0018","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ghir.2015.06.006","article-title":"Reviewing the safety of GH replacement therapy in adults","volume":"25","author":"Stochholm","year":"2015","journal-title":"Growth Horm IGF Res."},{"issue":"1","key":"2022061616021303000_CIT0019","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1530\/eje.1.02179","article-title":"Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - a KIMS database analysis","volume":"155","author":"Abs","year":"2006","journal-title":"Eur J Endocrinol."},{"issue":"6","key":"2022061616021303000_CIT0020","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1530\/EJE-08-0448","article-title":"GH replacement in hypopituitarism improves lipid profile and quality of life independently of changes in obesity variables","volume":"159","author":"Abrams","year":"2008","journal-title":"Eur J Endocrinol."},{"issue":"4","key":"2022061616021303000_CIT0021","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1530\/EJE-09-0836","article-title":"Clinical features of GH deficiency and effects of 3 years of GH replacement in adults with controlled Cushing\u2019s disease","volume":"162","author":"Hoybye","year":"2010","journal-title":"Eur J Endocrinol."},{"issue":"6","key":"2022061616021303000_CIT0022","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1210\/jc.2014-1013","article-title":"Effects of long-term growth hormone replacement in adults with growth hormone deficiency following cure of acromegaly: a KIMS analysis","volume":"99","author":"Tritos","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2022061616021303000_CIT0023","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000499430","article-title":"Improvements in body composition after 4 years of growth hormone treatment in adult-onset hypopituitarism compared to age-matched controls","volume":"109","author":"Postma","year":"2019","journal-title":"Neuroendocrinology."},{"issue":"1","key":"2022061616021303000_CIT0024","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1530\/eje.1.02176","article-title":"Does long-term GH replacement therapy in hypopituitary adults with GH deficiency normalise quality of life?","volume":"155","author":"Koltowska-Haggstrom","year":"2006","journal-title":"Eur J Endocrinol."},{"issue":"6","key":"2022061616021303000_CIT0025","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1530\/EJE-07-0631","article-title":"Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia","volume":"157","author":"Ho","year":"2007","journal-title":"Eur J Endocrinol."},{"issue":"2","key":"2022061616021303000_CIT0026","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1530\/eje.1.01829","article-title":"Consensus statement on the management of the GH-treated adolescent in the transition to adult care","volume":"152","author":"Clayton","year":"2005","journal-title":"Eur J Endocrinol."},{"key":"2022061616021303000_CIT0027","author":"Parkin"},{"key":"2022061616021303000_CIT0028","author":"Curado"},{"key":"2022061616021303000_CIT0029","author":"Forman","year":"2014"},{"key":"2022061616021303000_CIT0030","author":"Bray"},{"key":"2022061616021303000_CIT0031","author":"Johannsson","year":"2021"},{"issue":"1","key":"2022061616021303000_CIT0032","first-page":"107","article-title":"The Australian multicenter trial of growth hormone (GH) treatment in GH-deficient adults","volume":"83","author":"Cuneo","year":"1998","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2022061616021303000_CIT0033","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1210\/jc.2012-2684","article-title":"Prospective safety surveillance of GH-deficient adults: comparison of GH-treated vs untreated patients","volume":"98","author":"Hartman","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"key":"2022061616021303000_CIT0034","doi-asserted-by":"crossref","DOI":"10.1007\/s40618-020-01308-3","article-title":"Safety and effectiveness of Omnitrope(R) in patients with growth hormone deficiency: snapshot analysis of PATRO Adults study in the Italian population","author":"Arosio","year":"2021","journal-title":"J Endocrinol Invest."},{"key":"2022061616021303000_CIT0035","volume-title":"Genotropin\u00ae (somatropin [rDNA origin] for injection) Prescribing Information","year":"2019"},{"issue":"11","key":"2022061616021303000_CIT0036","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.4158\/GL-2019-0405","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care","volume":"25","author":"Yuen","year":"2019","journal-title":"Endocr Pract."},{"issue":"4","key":"2022061616021303000_CIT0037","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1046\/j.1365-2265.1997.1660984.x","article-title":"The safety profile of GH replacement therapy in adults","volume":"46","author":"Chipman","year":"1997","journal-title":"Clin Endocrinol."},{"issue":"2","key":"2022061616021303000_CIT0038","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1046\/j.1365-2265.2000.00931.x","article-title":"Insulin-like growth factor I administration induces fluid and sodium retention in healthy adults: possible involvement of renin and atrial natriuretic factor","volume":"52","author":"M\u00f8ller","year":"2000","journal-title":"Clin Endocrinol."},{"issue":"6","key":"2022061616021303000_CIT0039","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1210\/clinem\/dgab080","article-title":"Long-term safety of growth hormone treatment in childhood: two large observational studies: NordiNet IOS and ANSWER","volume":"106","author":"Savendahl","year":"2021","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2022061616021303000_CIT0040","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1365-2265.2005.02404.x","article-title":"Does growth hormone cause cancer?","volume":"64","author":"Jenkins","year":"2006","journal-title":"Clin Endocrinol."},{"issue":"2","key":"2022061616021303000_CIT0041","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1530\/EJE-11-0286","article-title":"Assessment of primary cancers in GH-treated adult hypopituitary patients: an analysis from the Hypopituitary Control and Complications Study","volume":"165","author":"Child","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2022061616021303000_CIT0042","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1530\/EJE-14-1123","article-title":"Incidence of primary cancers and intracranial tumour recurrences in GH-treated and untreated adult hypopituitary patients: analyses from the Hypopituitary Control and Complications Study","volume":"172","author":"Child","year":"2015","journal-title":"Eur J Endocrinol."},{"issue":"5","key":"2022061616021303000_CIT0043","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s11102-013-0529-6","article-title":"Adult mortality or morbidity is not increased in childhood-onset growth hormone deficient patients who received pediatric GH treatment: an analysis of the Hypopituitary Control and Complications Study (HypoCCS)","volume":"17","author":"Mo","year":"2014","journal-title":"Pituitary."},{"issue":"2","key":"2022061616021303000_CIT0044","doi-asserted-by":"crossref","first-page":"R19","DOI":"10.1530\/ERC-12-0219","article-title":"Thyroid hormone, thyroid hormone receptors, and cancer: a clinical perspective","volume":"20","author":"Moeller","year":"2013","journal-title":"Endocr Relat Cancer."},{"key":"2022061616021303000_CIT0045","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3389\/fendo.2019.00059","article-title":"Thyroid hormones and cancer: a comprehensive review of preclinical and clinical studies","volume":"10","author":"Krashin","year":"2019","journal-title":"Front Endocrinol."},{"issue":"9","key":"2022061616021303000_CIT0046","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41419-020-03009-4","article-title":"Glucocorticoids induce differentiation and chemoresistance in ovarian cancer by promoting ROR1-mediated stemness","volume":"11","author":"Karvonen","year":"2020","journal-title":"Cell Death Dis."},{"issue":"7749","key":"2022061616021303000_CIT0047","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41586-019-1019-4","article-title":"Glucocorticoids promote breast cancer metastasis","volume":"567","author":"Obradovic","year":"2019","journal-title":"Nature."},{"issue":"12","key":"2022061616021303000_CIT0048","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1158\/1940-6207.CAPR-20-0161","article-title":"Long-term glucocorticoid use and cancer risk: a population-based cohort study in South Korea","volume":"13","author":"Oh","year":"2020","journal-title":"Cancer Prev Res."},{"issue":"2","key":"2022061616021303000_CIT0049","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1210\/jc.2017-01899","article-title":"New neoplasm during GH replacement in adults with pituitary deficiency following malignancy: a KIMS analysis","volume":"103","author":"Krzyzanowska-Mittermayer","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"issue":"22","key":"2022061616021303000_CIT0050","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.3748\/wjg.14.3484","article-title":"Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis","volume":"14","author":"Rokkas","year":"2008","journal-title":"World J Gastroenterol."},{"issue":"2","key":"2022061616021303000_CIT0051","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1530\/EJE-07-0164","article-title":"Influence of GH substitution therapy in deficient adults on the recurrence rate of hormonally inactive pituitary adenomas: a case control study","volume":"157","author":"Buchfelder","year":"2007","journal-title":"Eur J Endocrinol."},{"issue":"6","key":"2022061616021303000_CIT0052","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1530\/EJE-11-1028","article-title":"Overall and cause-specific mortality in GH-deficient adults on GH replacement","volume":"166","author":"Gaillard","year":"2012","journal-title":"Eur J Endocrinol."},{"key":"2022061616021303000_CIT0053","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3389\/fendo.2011.00032","article-title":"The intricate role of growth hormone in metabolism","volume":"2","author":"Vijayakumar","year":"2011","journal-title":"Front Endocrinol."},{"issue":"15","key":"2022061616021303000_CIT0054","doi-asserted-by":"crossref","first-page":"6983","DOI":"10.1073\/pnas.89.15.6983","article-title":"Importance of growth hormone for the induction of hepatic low density lipoprotein receptors","volume":"89","author":"Rudling","year":"1992","journal-title":"Proc Natl Acad Sci USA."},{"issue":"4","key":"2022061616021303000_CIT0055","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1210\/jc.2003-031474","article-title":"Effects of growth hormone (GH) replacement therapy on low-density lipoprotein apolipoprotein B100 kinetics in adult patients with GH deficiency: a stable isotope study","volume":"89","author":"Christ","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2022061616021303000_CIT0056","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/00041433-199405030-00002","article-title":"Growth hormone and hepatic lipoprotein metabolism","volume":"5","author":"Angelin","year":"1994","journal-title":"Curr Opin Lipidol."},{"issue":"1","key":"2022061616021303000_CIT0057","first-page":"307","article-title":"Effects of growth hormone (GH) replacement therapy on very low density lipoprotein apolipoprotein B100 kinetics in patients with adult GH deficiency: a stable isotope study","volume":"84","author":"Christ","year":"1999","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2022061616021303000_CIT0058","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0022-2275(20)32034-4","article-title":"Effect of growth hormone replacement therapy on plasma lecithin:cholesterol acyltransferase and lipid transfer protein activities in growth hormone-deficient adults","volume":"41","author":"Beentjes","year":"2000","journal-title":"J Lipid Res."},{"issue":"11","key":"2022061616021303000_CIT0059","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s40618-018-0860-x","article-title":"Analysis of characteristics and outcomes by growth hormone treatment duration in adult patients in the Italian cohort of the Hypopituitary Control and Complications Study (HypoCCS)","volume":"41","author":"Rochira","year":"2018","journal-title":"J Endocrinol Invest."},{"issue":"10","key":"2022061616021303000_CIT0060","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1507\/endocrj.EJ13-0083","article-title":"Efficacy and safety of growth hormone replacement therapy in Japanese adults with growth hormone deficiency: a post-marketing observational study","volume":"60","author":"Shimatsu","year":"2013","journal-title":"Endocr J."},{"issue":"1","key":"2022061616021303000_CIT0061","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ghir.2010.10.005","article-title":"The benefit of long-term growth hormone (GH) replacement therapy in hypopituitary adults with GH deficiency: results of the German KIMS database","volume":"21","author":"Spielhagen","year":"2011","journal-title":"Growth Horm IGF Res."},{"issue":"7","key":"2022061616021303000_CIT0062","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1507\/endocrj.EJ16-0604","article-title":"Safety and effectiveness of long-term growth hormone therapy in Japanese patients with adult growth hormone deficiency: a postmarketing, multicenter, observational study","volume":"64","author":"Shimatsu","year":"2017","journal-title":"Endocr J."},{"issue":"1","key":"2022061616021303000_CIT0063","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12902-020-0535-4","article-title":"Ten years with biosimilar rhGH in clinical practice in Sweden - experience from the prospective PATRO children and adult studies","volume":"20","author":"Lundberg","year":"2020","journal-title":"BMC Endocr Disord."},{"issue":"4","key":"2022061616021303000_CIT0064","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2174\/1871530317666170919121729","article-title":"GH supplementation effects on cardiovascular risk in GH deficient adult patients: a systematic review and meta-analysis","volume":"17","author":"Giagulli","year":"2017","journal-title":"Endocr Metab Immune Disord Drug Targets."},{"issue":"5","key":"2022061616021303000_CIT0065","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000491388","article-title":"European Thyroid Association (ETA) guidelines on the diagnosis and management of central hypothyroidism","volume":"7","author":"Persani","year":"2018","journal-title":"Eur Thyroid J"},{"issue":"9","key":"2022061616021303000_CIT0066","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1210\/jc.2013-1610","article-title":"Central hypothyroidism and its replacement have a significant influence on cardiovascular risk factors in adult hypopituitary patients","volume":"98","author":"Klose","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2022061616021303000_CIT0067","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s11102-020-01079-3","article-title":"Effect of long-term growth hormone replacement on glucose metabolism in adults with growth hormone deficiency: a systematic review and meta-analysis","volume":"24","author":"Zhou","year":"2021","journal-title":"Pituitary."},{"issue":"7","key":"2022061616021303000_CIT0068","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1210\/jc.2011-0448","article-title":"Prevalence and incidence of diabetes mellitus in adult patients on growth hormone replacement for growth hormone deficiency: a surveillance database analysis","volume":"96","author":"Attanasio","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2022061616021303000_CIT0069","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2337\/dc11-0449","article-title":"Incidence of diabetes mellitus and evolution of glucose parameters in growth hormone-deficient subjects during growth hormone replacement therapy: a long-term observational study","volume":"35","author":"Luger","year":"2012","journal-title":"Diabetes Care."},{"issue":"2","key":"2022061616021303000_CIT0070","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/cen.13256","article-title":"The effect of growth hormone (GH) replacement on blood glucose homeostasis in adult nondiabetic patients with GH deficiency: real-life data from the NordiNet((R)) International Outcome Study","volume":"86","author":"Weber","year":"2017","journal-title":"Clin Endocrinol."},{"issue":"1","key":"2022061616021303000_CIT0071","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12902-019-0464-2","article-title":"No increased risk of glucose metabolism disorders in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope(R)): data from an observational, longitudinal study","volume":"19","author":"Beck-Peccoz","year":"2019","journal-title":"BMC Endocr Disord."},{"issue":"1","key":"2022061616021303000_CIT0072","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1365-2265.2009.03612.x","article-title":"Occurrence of impaired fasting glucose in GH-deficient adults receiving GH replacement compared with untreated subjects","volume":"72","author":"Woodmansee","year":"2010","journal-title":"Clin Endocrinol."},{"issue":"1","key":"2022061616021303000_CIT0073","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cen.12477","article-title":"Efficacy and safety of growth hormone treatment in adults with growth hormone deficiency: a systematic review of studies on morbidity","volume":"81","author":"van Bunderen","year":"2014","journal-title":"Clin Endocrinol."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgac199\/43402845\/dgac199.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/7\/1906\/44110564\/dgac199.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/7\/1906\/44110564\/dgac199.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T15:45:51Z","timestamp":1700408751000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/107\/7\/1906\/6562793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,3]]},"references-count":73,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,4,3]]},"published-print":{"date-parts":[[2022,6,16]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgac199","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,1]]},"published":{"date-parts":[[2022,4,3]]}}}